NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free OPRX Stock Alerts $12.21 -0.48 (-3.78%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$11.92▼$12.6650-Day Range$12.69▼$16.1752-Week Range$6.92▼$16.65Volume174,687 shsAverage Volume111,866 shsMarket Capitalization$221.61 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get OptimizeRx alerts: Email Address OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside31.0% Upside$16.00 Price TargetShort InterestBearish4.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 4 Articles This WeekInsider TradingSelling Shares$60,760 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.66) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsComputer And Technology Sector363rd out of 603 stocksBusiness Services, Not Elsewhere Classified Industry55th out of 89 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, OptimizeRx has a forecasted upside of 31.0% from its current price of $12.21.Amount of Analyst CoverageOptimizeRx has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.88% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in OptimizeRx has recently increased by 0.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.0 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OptimizeRx this week, compared to 1 article on an average week.Search Interest2 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,760.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions77.82% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.66) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -15.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -15.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesMarch 18, 2024 | americanbankingnews.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)March 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 11, 2024 | markets.businessinsider.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023March 11, 2024 | globenewswire.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023March 6, 2024 | stockhouse.comOptimizeRx Powers Walmart's 'Specialty Pharmacies of the Community' Outreach EffortMarch 4, 2024 | globenewswire.comOptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach EffortFebruary 23, 2024 | benzinga.comOptimizeRx Stock (NASDAQ:OPRX), Short Interest ReportMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 21, 2024 | globenewswire.comOptimizeRx to Participate in Upcoming Investor ConferencesJanuary 9, 2024 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business UpdateJanuary 9, 2024 | finance.yahoo.comOptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business UpdateJanuary 4, 2024 | msn.comBarclays Initiates Coverage of OptimizeRx (OPRX) with Equal-Weight RecommendationJanuary 3, 2024 | realmoney.thestreet.comOptimizeRx initiated with neutral view at BarclaysDecember 26, 2023 | finance.yahoo.comShould You Exit OptimizeRx Corp. (OPRX)?December 23, 2023 | benzinga.comOptimizeRx Stock (NASDAQ:OPRX) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comOptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San FranciscoDecember 11, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?December 11, 2023 | finance.yahoo.comWith 74% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big gunsDecember 6, 2023 | msn.comWall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should KnowDecember 6, 2023 | finance.yahoo.comWall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should KnowNovember 21, 2023 | finance.yahoo.comWhy OptimizeRx Corp. (OPRX) Might be Well Poised for a SurgeNovember 20, 2023 | finance.yahoo.comHow Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%November 18, 2023 | morningstar.comOptimizeRx Corp OPRXNovember 14, 2023 | finance.yahoo.comIndustry Analysts Just Made A Massive Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Revenue ForecastsNovember 13, 2023 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on OptimizeRx (OPRX)See More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/19/2024Next Earnings (Estimated)3/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees109Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+31.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,440,000.00 Net Margins-21.88% Pretax Margin-21.88% Return on Equity-9.24% Return on Assets-8.71% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual Sales$62.45 million Price / Sales3.55 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book1.66Miscellaneous Outstanding Shares18,150,000Free Float17,353,000Market Cap$221.61 million OptionableOptionable Beta1.01 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. William J. Febbo (Age 55)CEO & Director Comp: $694.4kMr. Stephen L. Silvestro (Age 46)President Comp: $458.6kMr. Edward Stelmakh C.M.A. (Age 58)M.B.A., CFO & COO Comp: $547.05kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceMr. Todd Inman (Age 68)Chief Technology Officer Ms. Marion K Odence-Ford (Age 59)General Counsel & Chief Compliance Officer Comp: $428.12kMaira AlejandraMedia Relations ManagerMs. Sheryl KearneyHuman Resources ManagerMr. Terence J. Hamilton (Age 59)Senior Vice President of Pharma Comp: $441.63kDr. Doug Besch (Age 42)Chief Product Officer More ExecutivesKey CompetitorsRimini StreetNASDAQ:RMNILimelight NetworksNASDAQ:LLNWZeroFoxNASDAQ:ZFOXEmeraldNYSE:EEXDHI GroupNYSE:DHXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 28,416 shares on 3/11/2024Ownership: 5.625%Greenwood Capital Associates LLCBought 20,245 shares on 3/5/2024Ownership: 0.301%Goldman Sachs Group Inc.Sold 30,985 shares on 3/1/2024Ownership: 0.074%Quarry LPSold 4,188 shares on 2/20/2024Ownership: 0.021%Citadel Advisors LLCBought 1,700 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 7 brokers have issued 1-year target prices for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2024? OptimizeRx's stock was trading at $14.31 on January 1st, 2024. Since then, OPRX shares have decreased by 14.7% and is now trading at $12.21. View the best growth stocks for 2024 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The business earned $16.13 million during the quarter, compared to analyst estimates of $14.82 million. OptimizeRx had a negative net margin of 21.88% and a negative trailing twelve-month return on equity of 9.24%. During the same quarter in the previous year, the firm posted ($0.01) EPS. What ETFs hold OptimizeRx's stock? ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC). What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $110.4 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include First Light Asset Management LLC (9.52%), Vanguard Group Inc. (5.63%), Vanguard Group Inc. (5.63%), G2 Investment Partners Management LLC (2.58%), Dimensional Fund Advisors LP (1.41%) and Federated Hermes Inc. (1.01%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.